Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Neurons: The Cell Body and the Dendrites01:23

Neurons: The Cell Body and the Dendrites

6.7K
A typical nerve cell comprises three main components: the cell body, dendrites, and the axon. The cell body, also known as the soma or perikaryon, serves as the central biosynthetic hub housing a nucleus surrounded by cytoplasm containing organelles commonly found in most cells. Notably, Nissl bodies, clusters of the rough endoplasmic reticulum and free ribosomes responsible for protein synthesis, are distinctive features of the neuronal cell body. As neurons age, aggregates of a brown pigment...
6.7K
What are Cells?01:07

What are Cells?

198.1K
Cells are the smallest and basic units of life, whether it is a single cell that forms the entire organism, e.g., in a bacterium or trillions of them, e.g., in humans. No matter what organism a cell is a part of, they share specific characteristics.
Basic Characteristics of Cells
A living cell has a plasma membrane, a bilayer of lipids that separates the aqueous solution inside the cell called the cytoplasm from the outside environment.
Furthermore, a living cell possesses genetic information...
198.1K
What are Cells?01:15

What are Cells?

47.5K
Cells are the smallest and basic units of life, whether it is a single cell that forms the entire organism, e.g., in a bacterium, or trillions of them, e.g., in humans. No matter what organism a cell is a part of, they share specific characteristics.
Basic Characteristics of Cells
A living cell has a plasma membrane, a bilayer of lipids that separates the aqueous solution inside the cell called the cytoplasm from the outside environment.
Furthermore, a living cell possesses genetic information...
47.5K
Concentration Cells02:41

Concentration Cells

25.6K
A concentration cell is a type of a  voltaic cell constructed by connecting two almost identical half-cells, both based on the same half-reaction and using the same electrode, differing only in the concentration of one redox species. A concentration cell's potential, therefore, is determined only by the concentration difference of the particular redox species.
Consider the following voltaic cell:
25.6K
What is Cell Signaling?02:03

What is Cell Signaling?

129.9K
Despite the protective membrane that separates a cell from the environment, cells need the ability to detect and respond to environmental changes. Additionally, cells often need to communicate with one another. Unicellular and multicellular organisms use a variety of cell signaling mechanisms to communicate to respond to the environment.
129.9K
Chemistry of the Cell02:58

Chemistry of the Cell

47.5K
The cell is chemically composed of water, organic molecules and inorganic ions.
Water
The polarity of the water molecule and its resulting hydrogen bonding makes water a unique substance with special properties that are intimately tied to the processes of life. Life originally evolved in an aqueous environment, and most of an organism’s cellular chemistry and metabolism occur inside the aqueous contents of the cell’s cytoplasm. Special properties of water are its high heat capacity...
47.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Blood·2026
Same author

CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete Remission.

Blood advances·2026
Same author

Genetic Landscape of Acute Leukemia of Ambiguous Lineage: A Single Cancer Center Experience.

The Journal of molecular diagnostics : JMD·2026
Same author

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

The Clinicopathologic and Genomic Features of Mature Versus Blastic Plasmacytoid Dendritic Cell Neoplasms Arising From Chronic Myeloid Neoplasms.

The American journal of surgical pathology·2026
Same author

Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.

Blood advances·2026

Related Experiment Video

Updated: Jan 25, 2026

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow
08:01

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow

Published on: November 4, 2016

13.0K

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

Naveen Pemmaraju1, Andrew A Lane1, Kendra L Sweet1

  • 1From the University of Texas M.D. Anderson Cancer Center, Houston (N.P., M.D., H.M.K., M.K.); Dana-Farber Cancer Institute (A.A.L.) and Boston University School of Medicine (J.M.S.), Boston, and Veristat, Southborough (J.B.) - all in Massachusetts; H. Lee Moffitt Cancer Center, Tampa, FL (K.L.S., J.E.L.); City of Hope National Medical Center, Duarte, CA (A.S.S.); Ohio State University, Columbus (S.V.); Winship Cancer Institute of Emory University, Atlanta (W.B.); Duke University Medical Center, Durham, NC (D.A.R.); and Roswell Park Comprehensive Cancer Center, Buffalo (E.S.W.), and Stemline Therapeutics, New York (S. Spence, S. Shemesh, C.L.B., I.B.) - both in New York.

The New England Journal of Medicine
|April 25, 2019
PubMed
Summary

Tagraxofusp demonstrated clinical responses in adult patients with blastic plasmacytoid dendritic-cell neoplasm (BPDCN). Adverse events included capillary leak syndrome, hepatic dysfunction, and thrombocytopenia.

More Related Videos

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors
13:34

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors

Published on: March 17, 2014

11.5K
In Vitro Generation of Murine Plasmacytoid Dendritic Cells from Common Lymphoid Progenitors using the AC-6 Feeder System
08:18

In Vitro Generation of Murine Plasmacytoid Dendritic Cells from Common Lymphoid Progenitors using the AC-6 Feeder System

Published on: November 23, 2015

8.9K

Related Experiment Videos

Last Updated: Jan 25, 2026

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow
08:01

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow

Published on: November 4, 2016

13.0K
Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors
13:34

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors

Published on: March 17, 2014

11.5K
In Vitro Generation of Murine Plasmacytoid Dendritic Cells from Common Lymphoid Progenitors using the AC-6 Feeder System
08:18

In Vitro Generation of Murine Plasmacytoid Dendritic Cells from Common Lymphoid Progenitors using the AC-6 Feeder System

Published on: November 23, 2015

8.9K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive hematologic malignancy.
  • It arises from transformed plasmacytoid dendritic cells overexpressing IL3RA (CD123).
  • Tagraxofusp is a novel CD123-directed cytotoxin targeting BPDCN cells.

Purpose of the Study:

  • To evaluate the efficacy and safety of tagraxofusp in patients with BPDCN.
  • To determine response rates and duration of response in untreated and relapsed BPDCN patients.
  • To assess tagraxofusp's potential as a treatment for this rare cancer.

Main Methods:

  • An open-label, multicohort study involving 47 patients with BPDCN.
  • Patients received intravenous tagraxofusp (7 μg or 12 μg/kg) on days 1-5 of a 21-day cycle.
  • Treatment continued until disease progression or unacceptable toxicity.

Main Results:

  • In previously untreated patients receiving 12 μg/kg, 72% achieved the primary outcome (complete response/clinical complete response) with a 90% overall response rate.
  • Survival rates at 18 and 24 months were 59% and 52%, respectively, in this group.
  • Previously treated patients showed a 67% response rate and 8.5 months median overall survival.

Conclusions:

  • Tagraxofusp induced clinical responses in adult patients with untreated or relapsed BPDCN.
  • Common adverse events included elevated liver enzymes and thrombocytopenia.
  • Serious adverse events like capillary leak syndrome occurred, necessitating careful monitoring.